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Abstract Myocardial ischemia is recognized as an impor-
tant mechanism increasing the risk for cardiovascular events
in both symptomatic and asymptomatic patients. In addition
to obstructive coronary diseases, systemic inflammation,
macro- and microvascular function are additional important
mechanisms contributing to the ischemic myocardium.
Accumulating evidence indicates that coronary flow reserve
(CFR) is a quantitative measurement of ischemia including
integrated information on structure and function of the cor-
onary artery at all levels. Not surprisingly, CFR has been
shown to confer strong prognostic value for hard cardiovas-
cular (CV) events in a number of relevant patient cohorts.
Using high-resolution imaging, it is now possible to study
coronary arteries from mouse to man. Therefore, CFR may
be an important translational tool to risk-stratify patients and
to perform both preclinical and clinical proof-of-concept
studies before investing in large-scale outcome trials, thus
improving the translational value for novel CV targets.
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Introduction
During the last decade, a decline in age-adjusted cardiovas-
cular (CV) mortality has been observed [1]. Increasing pub-
lic awareness as well as recent advancement in medical and
surgical interventions are considered contributing factors to
this positive trend. However, ischemic cardiovascular dis-
ease remains the number one killer in the westernized world
and increasing prevalence of diabetes and obesity is believed
to accelerate the global cardiovascular disease burden [2].
There is accumulating evidence indicating that myocardi-
al ischemia is an important cause associated with residual
CV risks among both symptomatic and asymptomatic CAD
[3, 4]. Indeed, transient ischemia could also lead to sudden
death due to lethal arrhythmia [5–7]. In the setting of chronic
stable ischemic heart disease, angiogram-guided percutane-
ous coronary intervention (PCI) has not been shown to
deliver superior benefits compared to optimal medical treat-
ment, while a fractional flow reserve (FFR)-guided ap-
proach, which measures the hemodynamic significance of
stenosis, has begun to demonstrate promising results (FAME
II) [8].
Acute myocardial infarction (MI) is considered an
atherothrombotic event, which in turn is under the influence
of three major triggers according to Virchow’s triad: vessel
injury either through plaque rupture or endothelial erosion,
hypercoagulability and finally reduced and/or disturbed flow
[9, 10]. In the arterial system with normal blood flow veloc-
ity around 1 m/s, flow-stopping atherothrombosis is rare,
while in the venous system with slow and occasionally
stagnated flow, thrombosis may occur without atherosclero-
sis. In contrast to most other arteries, where flow occurs
predominantly in systole, coronary perfusion is mainly a
diastolic event. Also, the normal blood flow velocity in the
epicardial coronary arteries is much lower than in for exam-
ple: aorta and carotid arteries [11]. The unique anatomy and
physiology of the coronary circulation require specialized
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physiological adaptations. Understanding the biology of the
coronary vascular bed may help us to risk stratify patients as
well as identify novel treatment regimes to combat coronary
artery disease.
Concept of Coronary Flow Reserve
The concept of coronary flow reserve (CFR) was introduced to
reflect themaximal oxygen delivery capacity during increasing
demand. Since cardiomyocytes are capable of extracting oxy-
gen with great efficiency already at rest, the only way of
meeting increasing demand is to increase coronary blood flow
[11, 12]. At rest, there is a significant autoregulation in the
coronary vascular bed which ensures sufficient blood supply to
the cardiomyocytes under a wide range of perfusion pressure.
Thus, resting coronary blood flow is mainly under control of
tissue metabolic demand [13]. To test the maximum flow
reserve capacity, the autoregulation must be uncoupled, which
will create a linear relationship between perfusion pressure and
flow. Thus, CFR is usually measured during either exercise
challenge or pharmacological stimuli such as dobutamine and
adenosine [14].
Hemodynamically significant coronary lesions are known
to cause reduced CFR [12, 14]. In the case of diffuse coronary
artery atherosclerosis without angiogram-visible significant
stenosis, CFR could be an objective tool to assess the hemo-
dynamic significance, not necessarily reflected by distinct
local stenosis. This has been comprehensively described by
Dr. Gould et al., who pioneered the concept in humans [15].
However, impaired CFR could be due to many other patho-
logical conditions, such as microvascular dysfunction in for
example: diabetic patients [16]. Interestingly, the presence of
thin cap fibroma in the coronary artery has been reported to be
associated with impaired CFR, indicating an important but not
completely surprising link between atherosclerotic lesion
composition and downstream vascular function [17].
While FFR seems to be a fit-for-purpose tool to address
hemodynamic consequences of focal lesions, CFR could be a
measure of the entire coronary vascular functionality. Even
though there is correlation between CFR and FFR, signifi-
cant discrepancy between these two measures is evident,
which may suggest that they indeed reflect distinct aspects
of the coronary arteries [18]. This means that not all patients
with impaired CFR would have any intervenable coronary
lesions according to FFR, and that CFR will not necessarily
be improved even following the best FFR-guided PCI
procedure.
Even though myocardial perfusion scintigram (MPS) is
considered the gold-standard for assessment of myocardial
ischemia, the method relies on flow-redistribution during
stress testing when a hemodynamically significant stenosis
is present. In the case of balanced three vessel disease and
microvascular dysfunction, MPS results are less reliable in
term of identifying the high risk patient [19]. CFR as an
objective quantitative tool, will assess the hemodynamic
significance of angiographic moderate or ambiguous steno-
sis, as well as diagnose microvascular diseases (Fig. 1) [15].
Methods to Assess CFR in Man
Coronary flow reserve can be measured using many modal-
ities. Thermodilution was one of the invasive techniques
used to determine CFR in man [20]. Coronary flow velocity
reserve (CFVR) can be measured using invasive Doppler-
guide wires using, for example adenosine as a stress agent
[21]. Recently, a combined FFR and CFVR catheter has been
launched for simultaneous flow and pressure measurement
[22].
Non-invasive techniques have been developed during the
last two decades taking advantage of modern high-end im-
aging modalities. Positron emission tomography (PET) is
now established as the gold standard for absolute coronary
blood flow and flow reserve measurement. PET provides
both ischemia evaluation as well as absolute flow quantifi-
cation [23]. Various tracers can be used including those that
do not require a full-scale cyclotron facility, for example:
rubidium [24]. In combination with high-resolution comput-
er tomography (CT), this modality can provide both struc-
tural and functional information about ischemic heart disease
[25]. Even though PET is an established approach to assess
CFR, radiation exposure as well as high equipment and
running cost limit its wide use. Contrast CT might be a
new modality for perfusion imaging. This method is also
associated with radiation although the level of radiation has
decreased substantially with the latest generation CT [26].
Magnetic resonance imaging is a non-radioactive valuable
method, capable of assessing CFR, but is relatively costly
and time-consuming [27].
Myocardial contrast echocardiography is an inexpensive
and non-radioactive method for measurement of CFR. When
image quality is adequate, CFVR as well as CFR can be
readily measured [28]. However, for accurate and reproduc-
ible quantification of CFVR and CFR, high-quality images
are required both during rest and hyperemia allowing con-
trast intensity measurement to derive flow velocity as well as
steady-state flow signals.
Transthoracic color Doppler echocardiography (TDE-
CFR) has been successfully used to measure coronary blood
flow velocity (CBFV) and CFVR [29]. With proper machine
setting and skilled hands, the technique is non-radioactive and
feasible in every echo-lab without need of contrast agent.
Using this approach, success rate is greatest in the left anterior
descending (LAD) coronary artery. In addition, right posterior
descending coronary artery [30] as well as circumflex artery
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(LCX) CFBV is measurable [31]. Accuracy of these ap-
proaches has been validated previously against invasive tech-
niques [30]. Technically, for access to the distal LAD, only a
small echo-window is needed compared to for example: left
ventricle ejection fraction measurement using Simpson’s rule,
where a couple of cm echo-window is needed for good image
quality. Thus, obesity is not an absolute hurdle for the success
of this technique [32]. For real-life clinic use of this technique
for diagnosis of ischemic heart disease including obstructive
CAD and microvascular disease, dipyridamole-assisted TDE-
CFR has been successfully applied on a routine basis in
combination with wall motion analysis [33]. Using this ap-
proach, the high specificity of stress echo can be combined
with the high sensitivity of CFR for diagnosis of ischemic
heart disease in patients with suspect CAD.
For experimental purposes, LAD TDE-CFR has been
used for risk prediction as well as documentation of inter-
vention effects. Recently, our group showed excellent inter-
and intra-day variability of CBFV in a randomized double
blind clinical study [34]. During this study CBFV upon
increasing doses of adenosine was measured repeatedly. To
minimize environmental influences, all subjects stayed at the
clinical trial unit the evening prior to the examination and
received standardized meals etc. Thus, under controlled con-
ditions, variability for CFBV measurement using this ap-
proach was satisfactorily low (Coefficient of variance for
AUC for CBFV and adenosine doses <1 %) (Fig. 2).
Determinants of CFR in Man
To further understand biological processes and the clinical
relevance of CFR, numerous studies have been performed to
relate CFR to cardiovascular biomarkers. These studies re-
vealed that CFR indeed could serve as a composite physio-
logical marker of systemic CV risk. Besides obstructive
CAD, which is an obvious determinator of CFR [12, 14],
impaired CFR has been reported in patients with dilated
cardiomyopathy [35], as well as patients with diabetic vas-
cular complications [36]. Further, myocardial capillary den-
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Fig. 1 CFR provides an integrative assessment of coronary vascular
health at all levels of the vascular tree. Accumulating evidence suggests
that myocardial ischemia is the net result of pathophysiological mecha-
nisms within the epicardial vessels, resistance arteries and the capillaries.
In addition to diffuse or obstructive epicardial atherosclerosis, vascular
function and remodeling are important mechanisms contributing to over-
all myocardial perfusion. The microvasculature is influenced by systemic
inflammation such as leukocyte adhesion and neutrophil activation with
direct consequences on perfusion. Increased blood viscosity such as in
hyperlipidemic patients, has also direct implications on capillary flow
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CFR is rheologically associated with blood viscosity,
which in turn is dependent on lipoprotein and fibrinogen
levels. In familiar hypercholestoremic patients, CFR is related
to LDL level and is improved after LDL apheresis, supporting
the concept that increased blood viscosity due to extremely
high LDL level can be a determinant of CFR [38].
CFR has also been shown to correlate to markers of low
degree systemic inflammation, such as C-reactive protein [39]
and neutrophil count [40]. Based on large-scale genetic asso-
ciation studies, IL-6 has recently been shown to be causally
linked to CV outcome alongside LDL-regulating pathways
[41]. Interestingly, a PET-CFR study conducted in twins
showed that IL-6 indeed was a determinant of CFR in those
asymptomatic subjects [42].
It is well-known that endothelium plays a central role in
CV disease etiology and progression [43]. Even though CFR
is measured using a non-endothelium dependent vasodilator,
for example: adenosine, for achieving maximum hyperemic
flow response, intact endothelial function is required. CFR
has been shown to be associated with peripheral endothelial
function both in chest pain patients and in healthy volunteers
[44, 45] and direct inhibition of the nitric oxide pathway
reduced hyperemic response in healthy volunteers [46].
Prognostic Vaules of CFR in Man
Impaired CFR has been shown to confer great prognostic
information for hard CVoutcome, including all cause mortality,
CV death and non-fatal MI. Independent of imaging modality
used, the prognostic power of CFR appears to be consistent. In
post-MI setting, invasively assessed CFVR showed prognostic
value in the “DEBATE” study. In such a setting, microvascular
obstruction as well as infarct size may impact on CFVR along-
side residual ischemia [47]. This concept has been extensively
evaluated in patients with suspected coronary artery disease
since they are undergoing ischemia testing based on clinical
indication. In these patients, CFVR adds incremental prognos-
tic values on top of wall motion analysis in terms of prediction
of mortality and spontaneous CV events [33]. Interestingly, in
the paper by Murthy et al., PET-CFR magnitude dependently
predicted CV mortality across various levels of infarct size,
ischemic burden and LV ejection fraction [48]. These data
strongly supports the concept that CFR rather than just obstruc-
tive coronary artery disease contributes to CV vulnerability. In
line with this, Murthy et al. showed that diabetic subjects
without previous CAD but with impaired CFR had the same
risk as non-diabetic patients with CAD [49]. Further, CFR
showed great prognostic information in patients with dilated
cardiomyopathy [50], which suggests that impaired CFR is an
independent risk driving CV events in additional patient co-
horts. In the context of post-infarct cardiac remodeling, im-
paired CFR is an independent predictor of adverse left ventricle
remodeling [51]. The quantitative nature of CFR measurement
is also reflected in its prognostic information, since it has also
been shown that CVoutcome is related to CFR in a magnitude
dependent manner, that is the lower the CFR the worse the
outcome and vice versa [48].
Transplant vasculopathy is a phenomenon of diffuse coro-
nary artery disease for which traditional angiogram-based ap-
proaches cannot be used to follow the disease progression. In
these patients, CFVR has been successfully used as a prognos-
tic marker [52]. This further supports the concept that the
integrative physiological assessment of the coronary function-
ality is of greater importance than only the luminology-based
approaches.
Effects of Established Interventions on CFR in Man
That surgical by-pass or removal of hemodynamically sig-
nificant obstructive epicardial lesions can improve CFR is of
course a direct consequence of these procedures and follows
the purpose and definition of a successful revascularization
[53]. Other established CV treatments have also been shown
to improve CFR through mode of action impacting on mech-
anisms controlling CFR (Table 1).
LDL Apheresis
Blood viscosity lowering approaches, for example: LDL aphe-
resis, induce acute improvement of CFR in familiar hypercho-
lesterolemic patients with extraordinarily high cholesterol
levels [38].
Fig. 2 Adenosine dose versus mean coronary blood flow velocity re-
sponse pre-placebo (red dashed line, circle), post-placebo (red solid line,
triangle) and pre-ticagrelor (blue dashed line, circle). Red dashed and red
solid lines represent thus intra-day variability, whereas red dashed and
blue dashed lines represent inter-day variability (adapted from [34])
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Statins
Statins have shown both acute effects on CFR probably
through pleiotrophic effects but also in the medium-long
term, which most likely is due to their LDL-lowering anti-
atherosclerotic effects.
Anti-Hypertensives
Anti-hypertensive drugs such as angiotensin-converting en-
zyme blocker or receptor blockers have shown beneficial
effects on CFR through their effects on endothelium as well
as anti-inflammatory properties. Decreased afterload follow-
ing successful blood pressure normalization will also contrib-
ute to improvement of CFR due to reduced oxygen demand.
Anti-Inflammatory
In patients with increased systemic inflammation such as
reumatoid artheritis, blockade of IL-1 pathway using anankinra
immediately improved CFR and increased peripheral endothe-
lial function as measured by flow-mediated forearm vasodila-
tion as well as pulse wave velocity. Compared to prednisolon,
which did not show any impact on the cardiovascular system in
these patients, this treatment demonstrated sustained effects on
these endpoints also at one month follow-up. The beneficial
CV effects were also associated with a decrease in systemic
inflammatory markers.
Translational Aspects from a Drug Discovery Perspective
Discovery and development of novel anti-atherosclerotic drugs
to reduce cardiovascular events on top of standard of care is an
area of high risk. Several difficulties have to be overcome in
order to succeedwith delivering a positive outcome in phase III
trials. Traditionally, novel targets and compounds are validated
in pre-clinical models of atherosclerosis with the primary read-
out being a reduction in plaque progression/size. Often such
data provide the sole basis in terms of in vivo intervention data
before investing in large clinical programs. For clinical proof-
of-concept, primary end-points have focused on plaque centric
endpoints such as plaque volume, intima-media-thickness or
plaque composition. Although these endpoints are associated
with CV disease and CV events, limited information is avail-
able on how intervening with these endpoints affects CV
benefit. This is not surprising since, atherosclerotic plaques
are only one component contributing to the ischemic myocar-
dial event in humans. Many additional biological mechanisms
have been shown to play a role in triggering the event includ-
ing microvascular dysfunction, endothelial dysfunction, sys-
temic inflammation, vasospasm, thrombosis and angiogenesis
[67–70]. By using a more integrative approach for proof-of-
concept both pre-clinically and clinically, clinical development
could be potentially de-risked.
To study the effects of novel anti-atherosclerotic com-
pounds in animals within reasonable time frames, disease
progression needs to be accelerated by genetic manipulation
and/or feeding high-fat high-cholesterol containing diet. No
single animal model available today mimics all aspects of this
complex human disease and it is important to note in particular
that no model reliably and reproducibly replicates the rupture
and subsequent thrombotic occlusion of coronary arteries. As
discussed previously, the pathophysiological events that occur
at the level of the atherosclerotic plaques have been of great
interest during the past few decades and also in animal studies
targets which are involved in reducing plaque progression
have been in focus for potential future interventions for re-
ducing cardiovascular events. To gain confidence in potential
novel therapies for reducing CV events, it is crucial that pre-
clinical studies focus on the proper vascular bed and the
relevant translational endpoints. Despite the prevalent use of
mouse models of atherosclerosis, few have focused on the
coronary arteries due to technical difficulties with studying
these small arteries. Fortunately, due to recent advances with
high-resolution imaging, it is now possible to perform mor-
phological and functional imaging studies of cardiovascular
systems in living mice [71–74]. This has dramatically in-
creased the translational value of preclinical disease models
and may provide guidance for dose selection and Proof of
Principle studies in humans.
Despite the high heart rate in mouse, coronary flow ve-
locity can be measured in a reproducible way using high-
resolution color Doppler ultrasound. This technique has now
been applied in rodents and rabbits according to the human
protocol (Fig. 3). The flow profiles in mouse left coronary
artery (LCA) are strikingly human-like regarding amplitude,
duration and systolic/diastolic distribution [71]. Due to its
small size, little is known about coronary atherosclerosis and
its functional implications in mice. By using ultrasound
biomicroscopy the LCA can be visualized and the extent of
atherosclerosis determined in a non-invasive, longitudinal
way in living mice [75]. In a study performed in apoE/LDL
receptor-deficient mice the percent wall thickness in the
proximal LCA increased with age. Percent wall thickness
was significantly associated with color Doppler echocardi-
ography assessed mid- to distal coronary flow velocity ratios
(Fig. 4). The extent of coronary atherosclerosis in the prox-
imal LCAwas confirmed by histological sections and corre-
lated well with percent wall thickness and color Doppler
echocardiography velocity ratios.
Our group pioneered the work to establish the TDE-CFVR
approach in mice [71, 72, 74, 75] using high-resolution ultra-
sound. In addition to mid- to distal flow velocity ratio ap-
proach to determine LCA stenosis, CFVR can be determined
in mice in a similar way as in humans using color Doppler
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echocardiography. Hyperemia can be induced using adenosine
at 160 μg/kg/ml which is similar to the dose used in humans.
This dose was shown to induce hyperemia without any appar-
ent effects on systemic hemodynamics. Hypoxia is an alternate
non-invasive means of inducing a similar increase in CFVR. In
LDLR-deficient mice with coronary atherosclerosis, a correla-
tion could be found between the extent of lumen narrowing
and CFVR (Fig. 5) [72]. Although a correlation between
coronary atherosclerosis and CFVR was demonstrated in mice
it has also been shown that inflammation could impact on
CFVR, for example: CFVR is reduced following experimental
coxsackie virus-induced myocarditis [73].
Although similar protocols are used to study CFVR in
mice and humans, caution should be taken when comparing
the absolute magnitude of changes since anesthesia is nec-
essary in animal experiments and this has been shown to
influence CFR in rodents [76]. Indeed, the most commonly
used anesthetic agent isoflurane has been to shown to in-
crease CFBV per se [77]. To assess coronary artery function
in mice, CFVR is a good surrogate for CFR. In humans, a
Fig. 3 Representative ultrasound imaging of the LCA in human, rabbit,
rat and mouse. Upper panel: Color Doppler is used for identification of
the LCA. In the present imaging windows, the LCA is shown as bright
red-yellow streaks. White arrows indicate the site of the LCA where
pulsed Doppler is used to measure coronary blood flow velocity. Lower
panel: corresponding pulsed wave Doppler signals for measurements of
coronary blood flow velocity. Similar flow velocity patterns are evident
between the species with minor flow signal during systole and a major
flow signal during diastole. Flow velocity on y-axis (maximum velocity
100 cm/s in these images), time on x-axis
Fig. 4 Plaque growth with
increasing age in apoE/LDL
double knock-out mice in the
proximal (a,b,c) and mid-LCA
(d,e,f) and the correlation
between coronary artery
percentage wall thickness as
measured with histology and
proximal to mid flow velocity
ratio in the double knock-out
mice of different age (g). Scale
bar=300 μm. A typical color
Doppler image (h) showing site
of proximal stenosis (white
arrow) and stenosis-free segment
in the more distal parts of the
LCA (black arrow). Adapted
from [75] with permission
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good correlation between CFVR and CFR has been demon-
strated [78]. By measuring LCA lumen diameter and flow
velocity simultaneously in mice, a good correlation between
CFVR and CFR was evident. However, due to the larger
intra- and inter-observer variability in CFR measures, CFVR
is a more robust marker of coronary vascular health in mice
[74] (Fig. 6).
Effects of Interventions on CFR in Rodents
The TDE-CFR approach has also been developed and applied
in other species, for example: rat, to demonstrate effects of
various interventions. We showed that spontaneous hyperten-
sive rats improved their CFVR following voluntary endurance
training through increased vascular anti-oxidant capacity [79].
Improvement of CFVR was also associated with improved
vascular compliance and acetylcholine-mediated vasodilation
in peripheral vascular beds [80] (Fig. 7).
Statins have become a standard therapy for CV patients and
any novel therapy will need to demonstrate significant benefit
on top of statins. Thus, back translation of statin effects to
animal models is of fundamental importance for drug discov-
ery and development. In addition to their cholesterol lowering
effects, statins have been shown to retard the progression of
atherosclerosis [81], improve endothelial function [82], reduce
systemic inflammatory markers and reduce cardiovascular
mortality [82–84]. The response to statins in animal models
varies with species, strain, gender, diet and protocol used.
Although statins reduce plasma cholesterol and plaque area
in some murine models, the exact mechanisms behind the
cholesterol lowering effects are largely unknown. Statins have
shown to reduce atherosclerosis in the apoE*3Leiden by
changing lipoprotein profiles and total lipid levels [85, 86] in
plasma. However, the so called “pleiotropic effects” may also
play a significant role in this model [87]. In apoE- and LDLr-
deficient mouse strains, statins have shown variable results on
plasma cholesterol levels and plaque progression. ApoE-
deficient mice on a mixed C57BLl/6 and 129SvJ (Taconic
Fig. 5 Evidence of coronary artery atherosclerosis in the proximal
segment (a, b) but not the mid-segment (c) of the left coronary artery
in low-density lipoprotein receptor gene-deficient mice. A correlation
was evident between minimal lumen diameter and CFVR (d) as imaged
with high-resolution ultrasound. Arrowheads indicate coronary lesions.
Scale bar=200 μm. Adapted from [72] with permission
Fig. 6 CFR can be calculated from measurements of flow velocity
measurements with pulsed Doppler (a) (flow velocity on the y-axis and
time on the x-axis) and diameter measurements in B-MODE images
(total image width 3 mm) of the proximal to mid-segment (b) of the left
coronary artery in vivo. Arrowhead indicate site where the LCA diam-
eter was measured. There was a good correlation between CFVR and
CFR (c). Ao=Aorta, LCA=left coronary artery. Adapted from [74] with
permission
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Denmark) background on a high-fat diet (21 % pork lard and
0.15 % cholesterol) responded to rosuvastatin in a human like
manner. Plasma Cholesterol levels were reduced on average by
20 % during the 16-week study period [88]. In addition,
brachiocephalic plaque area and the inflammatory serum bio-
marker serum amyloid-A (SAA) were significantly reduced at
the end of the study suggesting additional effects similar to
those observed in humans. Assessing coronary artery flow,
calculated from UBM measured coronary diameter and color
Doppler echocardiography flow velocity revealed an increase
in hyperemic blood flow at the end of the study, again in line
with findings in humans. Generating data in this animal model
responding to statin therapy in a human-like way will improve
our confidence in novel targets and facilitate future translation-
al drug intervention studies in mice.
Grönros et al. used the TDE-CFVR approach to document
effects of a novel arginase inhibitor, which may act by restor-
ing normal nitric oxide balance in the vascular endothelium.
In a rat model of type 2 diabetes, microvascular dysfunction as
measured by CFVR was demonstrated relative to control rats.
Further, the arginase inhibitor succeeded to improve CFVR
only in diabetic rats and not in control rats [89].
CFR as a Translational Tool for Target Validation
We and others have shown that CFR in vivo is reduced in late
stage mouse atherosclerosis mouse models [72, 90], but also in
the absence of coronary arthrosclerosis such as in models of
diabetes [91], blood pressure overload induced heart failure
[92] and myocarditis [73]. CFR can thus be measured in
various disease models in vivo for exploration of disease mech-
anisms and might be used to validate novel drug targets.
5-Lipoxygenase (5-LO), five lipoxygenase activating pro-
tein (FLAP) and its products leukotrienes B4 (LTB4) and
cysteinyl leukotrienes (cys LTs) have been linked to cardio-
vascular disease [93]. The ALOX5AP (FLAP) haplotype
HapA has been associated with risk of MI [94] and levels of
5-LO, FLAP and LTA4H mRNA in human carotid plaques
have been correlated with the occurrence of plaque instability
Fig. 7 Ultrasound imaging of
the LCA in rat and improvement
in CFVR with exercise. Upper
panel (a–c): Color Doppler
images from baseline (a), low




CFVR and adenosine dose–
response curves for voluntarily
exercising spontaneous
hypertensive rats (solid line) vs
non-exercising controls (dashed
line) (g). As evident, voluntary
exercising rats had higher CFVR
compared with controls after
6 weeks. **p<0.01. Adapted
from [79] with permission
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[95]. In a phase II study, the 5-LO inhibitor, VIA-2291 re-
duced coronary plaque volume and new formation of rapidly
growing coronary lesions in ACS patients following 6-months
treatment [96]. These findings are in great agreement with
many preclinical studies performed in animal models of ath-
erosclerosis [97, 98].
To further explore the potential role of the 5-LO pathway in
low degree subclinical inflammation and coronary vascular
function, we carefully investigated CV function in 5-LOX-
deficient mice (AstraZeneca Transgenic Centre, Mölndal,
Sweden). We hypothesized that these mice could be protected
from deleterious effects of lipopolysaccharide (LPS) chal-
lenge in a low-grade inflammatory, sub-acute setting.
Adenosine-induced CFVR, cardiac function and morphol-
ogy were measured before and one week after LPS-challenge
(2 mg/kg) in 5-LOX−/− and in back-crossed littermate
C57BL/6 wild-type mice. Several cytokines and ex vivo aortic
endothelial function were measured one week after LPS chal-
lenge to avoid acute sepsis-like condition. Cardiac function
(not shown) and CFVR did not differ between the groups
before the LPS challenge. However, one week after LPS
challenge, CFVR was decreased in WT mice (p<0.05) while
no significant change was evident in 5-LOX−/− mice (Fig. 8).
In vivo cardiac measurements were similar after LPS (not
shown). Ex vivo aortic acetylcholine-mediated relaxation ca-
pacity in phenylephrine pre-contracted segments of the thorac-
ic aorta was impaired inWTmice compared to 5-LOX−/−mice
post LPS (p<0.01). Levels of IL-10 were higher in the plasma
of 5-LO−/− mice compared to WT mice post LPS (p<0.05).
Higher doses of LPS might induce septic shock with acute
effects such as myocardial contractile dysfunction, drop in
systemic blood pressure, vasoplegia, tissue hypoperfusion,
microvessel injury and multiple organ injury [99], whilst low
or moderate doses of LPS have been shown to induce endo-
thelial dysfunction in experimental settings [100]. Our data
seems to be consistent with the previous findings that 5-
LOX-deficient mice maintain blood pressure control better
than control mice [101] and rats treated with a 5-LO inhibitor
(Zileuton) showed reduced organ failure [99] following se-
vere LPS endotoxemia. In addition to mediating inflamma-
tion [93, 102], direct vasoactive actions of the LTs have been
frequently reported in both coronary [103] and aortic [101]
arteries of several species. Thus, 5-LO metabolites seem to
have both direct and indirect vasomodulating properties,
especially in abnormal conditions, as observed in atheroscle-
rotic arteries of humans [103]. Taken together, in addition to
its anti-atherosclerotic effects, 5-LO pathway inhibition may
also improve coronary vascular function in patients with
systemic low-grade inflammation.
Concluding Remarks
In summary, accumulating evidence indicates that CFR may
serve as a composite marker for coronary macro- and micro-
vascular status, as well as systemic risk profile. Quantitative
measurement of CFR provides us with an accurate prognostic
tool to risk stratify patients as well as to follow disease pro-
gression and potential effects of intervention. Mechanistically,
CFR is closely associated with many major pathoetiological
factors driving residual risk in CV patients, such as epicardial
vessel atherosclerosis burden and composition, left ventricle
hypertrophy, vascular rarefaction, dyslipidemia, subclinical in-
flammation, endothelial dysfunction, etc. Establishment of the
translational imaging techniques opens up exciting possibilities
for deepened mechanistic understanding of this important path-
ophysiological phenomenon. Accumulated knowledge will
hopefully accelerate development of novel therapeutic ap-
proaches targeting unexplored pathways to improve CFR and
thereby further reduce CV mortality and morbidity. A transla-
tional approach and comprehensive understanding of the biol-
ogy may potentially de-risk clinical development programs of
Fig. 8 CFVR in the LCA in vivo
before (pre) and after (post) LPS
challenge (a) and ex vivo aortic
relaxation capacity with
increasing doses of acetycholin
(Ach) (b) in 5-LO KO mice after
LPS challenge. *p<0.05,
**p<0.01
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novel therapies. In addition to treatment correcting dyslipidemia
and emerging drugs to reduce systemic inflammation, recent
scientific progress within regenerative medicine may also in the
not too distant future contribute to step-change therapies in terms
of for example: regeneration of cardiomyocytes and coronary
microvessels, and thereby restore a functional myocardiumwith
well-dimensioned vascular bed.
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